Your AI-Trained Oncology Knowledge Connection!

Clinical Advances in Nasopharyngeal Carcinoma : Episode 9

Opinion

Video

September 18, 2024

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

Author(s):

Barbara Burtness, MD,Victoria M. Villaflor, MD

Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.

EP: 1.Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

EP: 2.Current Guidelines for Managing Nasopharyngeal Carcinoma

EP: 3.Overview of the JUPITER and POLARIS-2 Trials

EP: 4.Value of PD-L1 Biomarker in NPC

EP: 5.Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

EP: 6.Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

EP: 7.Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

EP: 8.Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

Now Viewing

EP: 9.Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP: 10.Clinical Scenario: Locally Recurrent NPC

EP: 11.Clinical Scenario: Metastatic EBV-Positive NPC

Video content above is prompted by the following:

What are the potential benefits of integrating PD-1 inhibitors into standard treatment protocols for NPC?

What does the future look like for PD-1 Inhibitors in NPC?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity

Latest Conference Coverage

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

Hematologists Highlight Notable Insights From the 2025 EHA Congress

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP: 1.Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

EP: 2.Current Guidelines for Managing Nasopharyngeal Carcinoma

EP: 3.Overview of the JUPITER and POLARIS-2 Trials

EP: 4.Value of PD-L1 Biomarker in NPC

EP: 5.Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

EP: 6.Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

EP: 7.Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

EP: 8.Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

EP: 9.Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP: 10.Clinical Scenario: Locally Recurrent NPC

EP: 11.Clinical Scenario: Metastatic EBV-Positive NPC

Newsletter

Latest CME

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Latest Conference Coverage